Evidence map›Paper›PMID 28580178›Full record

ArticleAntibodies (Basel, Switzerland)2015

Antibody Reactivity of B Cells in Lupus Patients with Increased Disease Activity and ARID3a Expression.

Julie M Ward, Judith A James, Yan D Zhao, Carol F Webb

Open access · goldAbstract read
In one paragraph

Article in Antibodies (Basel, Switzerland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Julie M WardImmunobiology and Cancer Research, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA.
Judith A JamesDepartment of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
Yan D ZhaoDepartment of Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
Carol F WebbImmunobiology and Cancer Research, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA.
Oklahoma Medical Research Foundation · USUniversity of Oklahoma Health Sciences Center · US

Funding

Tracking and Evaluation CoreU54GM104938 · NIGMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Robert Hal Scofield · 2013 to 2026
$68.2M
SNP Confirmation and High Throughput Genotyping CoreP30AR053483 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI GUTHRIDGE, JOEL MARVIN · 2007 to 2017
$6.7M
Pre-Clinical Studies to Identify SLE Therapeutic TargetsU19AI082714 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JAMES, JUDITH A · 2009 to 2018
$6.2M
Molecular Basis of Immunity - Kirschtein-NRSAT32AI007633 · NIAID · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI CUNNINGHAM, MADELEINE W. · 2001 to 2022
$4.0M
Science in a Culture of MentoringP30GM103510 · NIGMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JAMES, JUDITH A · 2012 to 2016
$3.9M
Bright Function in the Immune SystemR01AI044215 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI WEBB, CAROL F · 1999 to 2009
$2.4M
Understanding early events in lupus autoimmunity to aid preventionU01AI101934 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JAMES, JUDITH A · 2012 to 2016
$2.3M
Role of the transcription factor ARID3a in innate immune responsesR01AI118836 · NIAID · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI WEBB, CAROL F · 2017 to 2020
$1.5M
Role of the transcription factor ARID3a in lupusR21AI090343 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI WEBB, CAROL F · 2010 to 2011
$430k
NIAID NIH HHS R01 AI044215NIAID NIH HHS R01 AI118836NIAID NIH HHS R21 AI090343NIAID NIH HHS T32 AI007633NIAID NIH HHS U01 AI101934NIAID NIH HHS U19 AI082714NIAMS NIH HHS P30 AR053483NIGMS NIH HHS P30 GM103510NIGMS NIH HHS U54 GM104938
6 · The paper itself

Abstract

Earlier studies showed that the DNA-binding protein, Bright/ARID3a bound to a subset of human and mouse immunoglobulin heavy chain promoters where it enhanced expression. Indeed, mice with transgenic expression of ARID3a in all B lymphocytes have expanded MZ B cells and produce anti-nuclear antibodies (ANAs). Consistent with our findings in mice, we observed that human systemic lupus erythematosus (SLE) patients had expanded numbers of peripheral blood ARID3a

Indexed as

antibodiesARID3aautoantigensSLE

Identifiers

PMID28580178
PMCPMC5451160
OpenAlexW2204964441

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.